6-Chloronaphthalene-2-carbonitrile | 1261626-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-Chloronaphthalene-2-carbonitrile
• CAS: 1261626-91-8
• 化学式: C₁₁H₆ClN
• 分子量: 187.62
• InChiKey: VIJMEUNAVBOWBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD<br/>[FR] INHIBITEURS DE BET POUR MODULER L'EXPRESSION DE DUX4 DANS LA FSHD
  申请人：UNIV SAINT LOUIS

  公开号：WO2020132004A1

  公开（公告）日：2020-06-25

  The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

  本公开提供了以下式的BET抑制剂：其中变量在此处定义，以及其药物组合物。本公开还提供了治疗患者的方法，包括给予溴和额外端（BET）结构域抑制剂治疗FSHD以调节DUX4表达。在某些实施例中，本方法包括使用一个或多个BET抑制剂作为FSHD患者的治疗剂，包括正在接受一种或多种缓解治疗（如治疗和/或导致肌肉增加的药物）的患者。
• COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF
  申请人：Hefei Industrial Pharmaceutical Institute Co., Ltd

  公开号：EP3708568A1

  公开（公告）日：2020-09-16

  The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

  本公开涉及药物化学领域，尤其涉及一类抑制磷酸二酯酶4(I)的小分子化合物、其制备方法以及包含该化合物的药物组合物。药效学试验证明，本公开的化合物具有抑制 PDE-4 酶的活性和治疗炎症的疗效。
• Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof
  申请人：Hefei Industrial Pharmaceutical Institute Co., Ltd.

  公开号：US11161860B2

  公开（公告）日：2021-11-02

  The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

  本公开涉及药物化学领域，尤其涉及一类抑制磷酸二酯酶4(I)的小分子化合物、其制备方法以及包含该化合物的药物组合物。药效学试验证明，本公开的化合物具有抑制 PDE-4 酶的活性和治疗炎症的疗效。
• COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
  申请人：Hefei Industrial Pharmaceutical Institute Co., Ltd.

  公开号：US20210179640A1

  公开（公告）日：2021-06-17

  The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.